Oasmia Pharmaceutical AB is a clinical-stage biopharmaceutical company that develops innovative therapies based on its proprietary XR-17 nanomicellar formulation technology. The company’s core focus is on improving drug solubility and bioavailability by encapsulating active compounds within a unique micellar system, enabling enhanced delivery and reduced side effects. Oasmia’s pipeline spans both human oncology and veterinary medicine, reflecting its commitment to addressing unmet medical needs across species.
Among its key products, Apealea® (paclitaxel micellar) has received marketing authorization in Europe for the treatment of ovarian cancer, marking a significant milestone in Oasmia’s evolution from research-stage investigator to commercial-stage developer. In veterinary medicine, Oasmia markets Paccal Vet, a paclitaxel formulation for canine mammary cancer, and Doxophos Vet, a doxorubicin-based therapy, both of which leverage the company’s nanomicellar platform to improve therapeutic outcomes in animals.
Founded in 1999 and headquartered in Uppsala, Sweden, Oasmia maintains research and development facilities in Europe and North America. The company has established strategic partnerships to expand its global reach, including collaborations in the United States, Asia and Latin America. These alliances support Oasmia’s commercialization efforts and bolster its capacity to navigate regulatory pathways across multiple jurisdictions.
Oasmia is led by a seasoned management team with extensive experience in pharmaceutical development, commercialization and corporate finance. President and Chief Executive Officer Klas Nordling, supported by Chief Financial Officer Mikael Jacobs, spearheads the company’s strategic direction. Under their leadership, Oasmia continues to advance its clinical programs and explore new applications for its XR-17 technology platform.
AI Generated. May Contain Errors.
